Volver a Agenda
Session Chair(s)
Matthew D. Rotelli, PHD, MS
Vice President, Bioethics
Eli Lilly and Company, United States
Learning Objective : Explain the critical importance of sensitivity analyses on various design feature decisions in comparative effectiveness research; Describe a framework by which more assessment of design features could be better assessed prior to study conduct as part of study feasibility assessment.
Speaker(s)
Feasibility of Comparative Effectiveness Research: Unmeasured Confounding and Operational Characteristics
Douglas E Faries, PHD
Eli Lilly and Company, United States
Research Fellow, Global Statistical Sciences
Additional Steps for Feasibility and Pre-Indentifying Sensitivity Analyses Prior to Launching CER
Cynthia J. Girman, DrPH
CERobs Conmsulting, LLC, United States
President
Discussant
Robert T. O'Neill, PHD
FDA, United States
Senior Statistical Advisor, Office of Translational Sciences, CDER
¿Tiene una cuenta?